Pharma Mar
€71.40Change from previous close: +0.92%Absolute change: +€0.65
At a glance
- Revenue growth
- +26.61%
- 2025 vs 2024
- Net income growth
- +187.03%
- 2025 vs 2024
- Net margin
- 33.9%
- 2024: 14.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 221 | 175 | 158 | 196 | 230 |
| Cost of revenue | 12.3 | 8.2 | 9.6 | 13.6 | 16.4 |
| Gross profit | 209 | 167 | 149 | 183 | 213 |
| Selling, general and administrative | 59.4 | 47.2 | 41.8 | 43.2 | 39.7 |
| Research and development | 95.2 | 104 | 99.3 | 83.4 | 72.2 |
| Operating income | 60.7 | 6.5 | -3.8 | 42.1 | 92.4 |
| EBIT | 60.7 | 6.5 | -3.8 | 42.1 | 92.4 |
| EBITDA | 66.5 | 10.1 | -1.1 | 44.9 | 95.0 |
| Interest expense | 2.5 | 2.5 | 2.4 | 2.4 | 3.4 |
| Pre-tax income | 59.7 | 12.0 | -3.6 | 43.8 | 95.1 |
| Income tax | -15.3 | -14.1 | -4.8 | -5.6 | 2.3 |
| Net income | 75.0 | 26.1 | 1.1 | 49.4 | 92.9 |
| Net income to common shareholders | 75.0 | 26.1 | 1.1 | 49.4 | 92.9 |
| Basic EPS | 4.30 | 1.49 | 0.06 | 2.73 | 5.14 |
| Diluted EPS | 4.30 | 1.49 | 0.06 | 2.73 | 5.13 |
| Average shares (basic) | 17.4 | 17.5 | 17.9 | 18.1 | 18.1 |
| Average shares (diluted) | 17.5 | 17.6 | 17.9 | 18.1 | 18.1 |
| Dividend per share | 1.00 | 0.80 | 0.65 | 0.65 | 0.65 |